SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-17-253552
Filing Date
2017-08-10
Accepted
2017-08-10 07:06:45
Documents
47
Period of Report
2017-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q d313418d10q.htm 10-Q 259461
2 EX-31.1 d313418dex311.htm EX-31.1 5995
3 EX-32.1 d313418dex321.htm EX-32.1 3128
  Complete submission text file 0001193125-17-253552.txt   1993710

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE DOCUMENT rxii-20170630.xml EX-101.INS 322978
5 XBRL TAXONOMY EXTENSION SCHEMA rxii-20170630.xsd EX-101.SCH 26292
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE rxii-20170630_cal.xml EX-101.CAL 34990
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE rxii-20170630_def.xml EX-101.DEF 104422
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE rxii-20170630_lab.xml EX-101.LAB 221344
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rxii-20170630_pre.xml EX-101.PRE 161674
Mailing Address 257 SIMARANO DRIVE SUITE 101 MARLBOROUGH MA 01752
Business Address 257 SIMARANO DRIVE SUITE 101 MARLBOROUGH MA 01752 (508) 767-3861
RXi Pharmaceuticals Corp (Filer) CIK: 0001533040 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36304 | Film No.: 171019682
SIC: 2834 Pharmaceutical Preparations